We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Regulatory News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.40
Bid: 10.50
Ask: 12.00
Change: 0.00 (0.00%)
Spread: 1.50 (14.286%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 11.40
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) Redx Pharma plc

17 Mar 2020 14:30

RNS Number : 4869G
Redx Pharma plc
17 March 2020
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Redx Pharma plc ("Redx")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma plc

(d) Is the discloser the offeror or the offeree?

OFFEROR / OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

17 March 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES / NO / N/A

If YES, specify which:

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

1p ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

n/a

n/a

(2) Cash-settled derivatives:

 

n/a

n/a

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

n/a

n/a

 

TOTAL:

n/a

n/a

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

n/a

Details, including nature of the rights concerned and relevant percentages:

n/a

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Interest of Redx Directors and connected advisers in Redx shares:

Name

Number of Shares

% of issued share capital

Iain Ross

600,000

0.32

Dr. Bernhard Kirschbaum

50,000

0.02

Peter Presland

120,000

0.06

WG Partners LLP

114,593

0.06

 

Interest of Redx Directors in options over Redx shares:

Name

No. of options

Exercise price

Vesting date

Expiry date

Lisa Anson

600,000

13.75p

4 June 2018

3 June 2028

Lisa Anson

600,000

20p

4 June 2018

3 June 2028

Lisa Anson

600,000

27p

4 June 2019

3 June 2028

Lisa Anson

600,000

35p

4 June 2019

3 June 2028

Lisa Anson

600,000

42.5p

4 June 2020

3 June 2028

Lisa Anson

600,000

50p

4 June 2020

3 June 2028

Dr. James Mead

200,000

13.75p

13 February 2019

12 February 2029

Dr. James Mead

200,000

20p

13 February 2019

12 February 2029

Dr. James Mead

200,000

27p

13 February 2020

12 February 2029

Dr. James Mead

200,000

35p

13 February 2020

12 February 2029

Dr. James Mead

200,000

42.5p

13 February 2021

12 February 2029

Dr. James Mead

200,000

50p

13 February 2021

12 February 2029

 

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

YES/NO

Supplemental Form 8 (SBL)

YES/NO

 

 

Date of disclosure:

17 March 2020

Contact name:

James Mead

Telephone number:

01625 496 609

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEEFLFLSVSIDLII
Date   Source Headline
24th Mar 202011:33 amRNSForm 8.5 - RedX Pharma Plc
24th Mar 20208:55 amRNSForm 8 (DD)
23rd Mar 20201:19 pmRNSHolding(s) in Company
23rd Mar 202012:37 pmRNSForm 8.5 - Redx Pharma Plc
23rd Mar 202011:45 amRNSForm 8.5 (EPT/RI)
23rd Mar 202010:42 amRNSForm 8 (DD) - Redx Pharma PLC
20th Mar 20204:37 pmRNSForm 8.3 - Redx Pharma plc
20th Mar 20204:30 pmRNSForm 8.3 - Redx Pharma
20th Mar 20201:55 pmRNSHolding(s) in Company
19th Mar 202011:45 amRNSForm 8.5 (EPT/RI)
18th Mar 20202:01 pmRNSForm 8.3 - Redx Pharma PLC
17th Mar 20202:54 pmRNSForm 8.3 - Seneca Partners Limited
17th Mar 20202:30 pmRNSForm 8 (OPD) Redx Pharma plc
17th Mar 20202:23 pmGNWForm 8.3 - AXA INVESTMENT MANAGERS: Redx Pharma PLC
17th Mar 20202:14 pmRNSForm 8.3 - RedX Pharma plc
17th Mar 202011:45 amRNSForm 8.5 (EPT/RI)
16th Mar 20205:31 pmRNSHolding(s) in Company
16th Mar 20205:30 pmRNSHolding(s) in Company
16th Mar 20202:47 pmRNSForm 8.3 - Redx Pharma plc
16th Mar 202011:45 amRNSForm 8.5 (EPT/RI)
16th Mar 20209:53 amRNSForm 8.3 - [REDX PHARMA PLC]
13th Mar 20207:37 amRNSHoldings in Company
13th Mar 20207:12 amRNSRECOMMENDED MANDATORY OFFER FOR REDX PHARMA PLC
13th Mar 20207:00 amRNSConfirmation of Private Approach
11th Mar 20207:00 amRNSFinal Results for Year Ended 30 September 2019
9th Mar 202010:05 amRNSHolding(s) in Company
2nd Mar 202011:45 amRNSForm 8.5 (EPT/RI)
2nd Mar 20207:00 amRNSRe-release: Funding Update
28th Feb 20206:29 pmRNSFunding update
28th Feb 20205:56 pmRNSTermination of discussions with Yesod Bio-Sciences
28th Feb 20204:57 pmRNSRule 2.8 Announcement
27th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
26th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
25th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
24th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
20th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
19th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
18th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
17th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
14th Feb 20204:16 pmRNSFurther statement re Rule 2.6 Extension
14th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
13th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
12th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
11th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
10th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
7th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
4th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
3rd Feb 20206:27 pmRNSForm 8.3 - RedX Pharma PLC
3rd Feb 202011:45 amRNSForm 8.5 (EPT/RI)
30th Jan 202011:45 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.